Literature DB >> 32199982

Structures of Bacterial MraY and Human GPT Provide Insights into Rational Antibiotic Design.

Ellene H Mashalidis1, Seok-Yong Lee2.   

Abstract

The widespread emergence of antibiotic resistance in pathogens necessitates the development of antibacterial agents inhibiting underexplored targets in bacterial metabolism. One such target is phospho-MurNAc-pentapeptide translocase (MraY), an essential integral membrane enzyme that catalyzes the first committed step of peptidoglycan biosynthesis. MraY has long been considered a promising candidate for antibiotic development in part because it is the target of five classes of naturally occurring nucleoside inhibitors with potent in vivo and in vitro antibacterial activity. Although these inhibitors each have a nucleoside moiety, they vary dramatically in their core structures, and they have different activity properties. Until recently, the structural basis of MraY inhibition was poorly understood. Several recent structures of MraY and its human paralog, GlcNAc-1-P-transferase, have provided insights into MraY inhibition that are consistent with known inhibitor activity data and can inform rational drug design for this important antibiotic target.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MraY; antibiotics; bacterial cell wall synthesis; membrane enzyme; nucleoside inhibitors

Mesh:

Substances:

Year:  2020        PMID: 32199982      PMCID: PMC8351759          DOI: 10.1016/j.jmb.2020.03.017

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  65 in total

1.  Synthesis of analogues of the O-beta-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 1: contribution of the amino group and the uracil moiety upon the inhibition of MraY.

Authors:  C Dini; N Drochon; S Feteanu; J C Guillot; C Peixoto; J Aszodi
Journal:  Bioorg Med Chem Lett       Date:  2001-02-26       Impact factor: 2.823

2.  Crystal structure of MraY, an essential membrane enzyme for bacterial cell wall synthesis.

Authors:  Jinshi Zhao; Robert A Gillespie; Ben C Chung; Do-Yeon Kwon; Ziqiang Guan; Jiyong Hong; Pei Zhou; Seok-Yong Lee
Journal:  Science       Date:  2013-08-30       Impact factor: 47.728

3.  Antibacterial Muraymycins from Mutant Strains of Streptomyces sp. NRRL 30471.

Authors:  Zheng Cui; Xiachang Wang; Stefan Koppermann; Jon S Thorson; Christian Ducho; Steven G Van Lanen
Journal:  J Nat Prod       Date:  2018-03-19       Impact factor: 4.050

4.  Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis.

Authors:  F Isono; M Inukai
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

5.  New pacidamycin antibiotics through precursor-directed biosynthesis.

Authors:  Sabine Grüschow; Emma J Rackham; Benjamin Elkins; Philip L A Newill; Lionel M Hill; Rebecca J M Goss
Journal:  Chembiochem       Date:  2009-01-26       Impact factor: 3.164

6.  Studies on novel bacterial translocase I inhibitors, A-500359s. III. Deaminocaprolactam derivatives of capuramycin: A-500359 E, F, H; M-1 and M-2.

Authors:  Yasunori Muramatsu; Shunichi Miyakoshi; Yasumasa Ogawa; Takashi Ohnuki; Michiko Miyazawa Ishii; Masatoshi Arai; Toshio Takatsu; Masatoshi Inukai
Journal:  J Antibiot (Tokyo)       Date:  2003-03       Impact factor: 2.649

Review 7.  Structural basis for selective inhibition of antibacterial target MraY, a membrane-bound enzyme involved in peptidoglycan synthesis.

Authors:  Jenny Hering; Elin Dunevall; Margareta Ek; Gisela Brändén
Journal:  Drug Discov Today       Date:  2018-05-18       Impact factor: 7.851

8.  Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin.

Authors:  Hitoshi Hotoda; Miyuki Furukawa; Makiko Daigo; Kazuhiro Murayama; Masakatsu Kaneko; Yasunori Muramatsu; Michiko Miyazawa Ishii; Shun-ichi Miyakoshi; Toshio Takatsu; Masatoshi Inukai; Masayo Kakuta; Tomomi Abe; Tamako Harasaki; Takashi Fukuoka; Yukio Utsui; Satoshi Ohya
Journal:  Bioorg Med Chem Lett       Date:  2003-09-01       Impact factor: 2.823

9.  Analogues of Muraymycin Nucleoside Antibiotics with Epimeric Uridine-Derived Core Structures.

Authors:  Anatol P Spork; Stefan Koppermann; Stephanie Schier Née Wohnig; Ruth Linder; Christian Ducho
Journal:  Molecules       Date:  2018-11-03       Impact factor: 4.411

10.  Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design.

Authors:  Yin Yao Dong; Hua Wang; Ashley C W Pike; Stephen A Cochrane; Sadra Hamedzadeh; Filip J Wyszyński; Simon R Bushell; Sylvain F Royer; David A Widdick; Andaleeb Sajid; Helena I Boshoff; Yumi Park; Ricardo Lucas; Wei-Min Liu; Seung Seo Lee; Takuya Machida; Leanne Minall; Shahid Mehmood; Katsiaryna Belaya; Wei-Wei Liu; Amy Chu; Leela Shrestha; Shubhashish M M Mukhopadhyay; Claire Strain-Damerell; Rod Chalk; Nicola A Burgess-Brown; Mervyn J Bibb; Clifton E Barry Iii; Carol V Robinson; David Beeson; Benjamin G Davis; Elisabeth P Carpenter
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

View more
  4 in total

1.  Peptidoglycan biosynthesis is driven by lipid transfer along enzyme-substrate affinity gradients.

Authors:  Abraham O Oluwole; Robin A Corey; Chelsea M Brown; Victor M Hernández-Rocamora; Phillip J Stansfeld; Waldemar Vollmer; Jani R Bolla; Carol V Robinson
Journal:  Nat Commun       Date:  2022-04-27       Impact factor: 17.694

2.  Synthesis and evaluation of cyclopentane-based muraymycin analogs targeting MraY.

Authors:  Seung-Hwa Kwak; Won Young Lim; Aili Hao; Ellene H Mashalidis; Do-Yeon Kwon; Pyeonghwa Jeong; Mi Jung Kim; Seok-Yong Lee; Jiyong Hong
Journal:  Eur J Med Chem       Date:  2021-02-06       Impact factor: 6.514

Review 3.  Identification and characterization of enzymes involved in the biosynthesis of pyrimidine nucleoside antibiotics.

Authors:  M McErlean; X Liu; Z Cui; B Gust; S G Van Lanen
Journal:  Nat Prod Rep       Date:  2021-07-21       Impact factor: 15.111

Review 4.  Cell Surface Biosynthesis and Remodeling Pathways in Mycobacteria Reveal New Drug Targets.

Authors:  Moagi Shaku; Christopher Ealand; Bavesh D Kana
Journal:  Front Cell Infect Microbiol       Date:  2020-11-12       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.